Skip to content
Screener

Kyverna Therapeutics, Inc. KYTX Operating Lease Liabilities (Current)

Operating Lease Liabilities (Current) at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$207M+6.7%
Climb Bio, Inc. logo
Climb Bio, Inc.CLYM
$263K+69.7%
Artiva Biotherapeutics, Inc. logo
Artiva Biotherapeutics, Inc.ARTV
$3.3M-6.7%
Iovance Biotherapeutics, Inc. logo
Iovance Biotherapeutics, Inc.IOVA
$2.67M-62.2%
Allogene Therapeutics logo
Allogene TherapeuticsALLO
$8.42M+10.3%
Vor Biopharma logo
Vor BiopharmaVOR
$307K-92.8%

Other financials

Income statement

See full
Operating income-$41.4M+12.7%
Net income-$39.7M+11.0%
EPS (diluted)-$0.66+35.9%

Balance sheet

See full
Cash & equivalents$32.2M-43.4%
Total debt$9.2M+32.1%
Total equity$195.6M-12.7%
Total assets$257.0M-1.4%

Cash flow

See full
Operating cash flow-$41.6M+7.4%
CapEx$2.0K-98.0%
Free cash flow-$33.5M+10.8%

Valuation

See full
Market cap$483.93M+261%
Enterprise value$460.9M+433%

Returns & leverage

See full
Return on equity-74.5%+74.4pp
Debt / equity0×0.0×
Current ratio8.1×+0.7×

Where this comes from

Reported directly by Kyverna Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:OperatingLeaseLiabilityCurrent.

The source filing: Kyverna Therapeutics, Inc.’s 10-Q, filed May 12, 2026.

Filed
May 12, 2026, 4:08 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001193125-26-219397
Line itemMarch 31, 2026December 31, 2025
Accrued compensation3,1149,990
Accrued license expense – related party3,7503,750
Other accrued expenses and current liabilities9,22213,472
Operating lease liabilities, short-term portion1,7643,662
Finance lease liabilities, short-term portion221307
Total current liabilities29,67436,487
Operating lease liabilities, net of short-term portion6,958320
Term loan24,81224,743

Item 1. Financial Statements (unaudited)

FAQ

What is Kyverna Therapeutics, Inc.'s operating lease liabilities (current)?
Kyverna Therapeutics, Inc. (KYTX) reported operating lease liabilities (current) of $1.76M in Q1 2026.
How has Kyverna Therapeutics, Inc.'s operating lease liabilities (current) changed year-over-year?
Kyverna Therapeutics, Inc.'s operating lease liabilities (current) decreased by 42.7% year-over-year, from $3.08M to $1.76M.
What is the long-term trend for Kyverna Therapeutics, Inc.'s operating lease liabilities (current)?
Over 2 years (2023 to 2025), Kyverna Therapeutics, Inc.'s operating lease liabilities (current) has grown at a 36.5% compound annual growth rate (CAGR), from $1.96M to $3.66M.
What does operating lease liabilities (current) mean?
The current portion of operating lease obligations due within one year, representing committed future lease payments under ASC 842.

Ask your AI about Kyverna Therapeutics, Inc.'s operating lease liabilities (current).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude